N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=232 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 92; 95 participants
N/A N=70 Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Helicobacter Pylori Infection
Primary: Eradication of H Pylori Infection 4 Weeks After Completion of Therapy — 23; 26 participants
N/A N=1,490 Blood Tests for Gastritis and Gastric Neoplasms
Cancer Screening Tests
Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale
Phase 3 N=119 ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
Dyspepsia · Helicobacter Pylori Infection
Primary: The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing — 59; 1; 7; 36 Participants — p=0.001
Phase 4 N=240 Sequential and Hybrid Therapies for H Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 94; 99 participants
N/A N=164 Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Helicobacter Pylori Infection
Primary: Percentage of Participants With Successful Eradication of H. Pylori — 91.4; 81.5 percentage of eradication
Phase 4 N=307 Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants With Complete Eradication of Helicobacter Pylori — 102; 100; 101 participants
Phase 3 N=455 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
Helicobacter Pylori Infection · Dyspepsia
Primary: Number of Participants With Eradication of H. Pylori — 191; 131 Participants — p=0.0001
Phase 2 N=40 Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content — 8.38; 7.72; 8.50; 7.29 percentage of liver fat content — p=0.94
N/A N=88 Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility
Infertility, Female
Primary: Quantitative Helicobacter Pylori IgG Assay in Serum — 70; 70 arbitrary unit per millilitre — p=<0.001
N/A N=51 Comparison of Two Rescue Therapies for Helicobacter Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 13; 21 participants
N/A N=102 Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 36; 49 participants — p=<0.001
Phase 2 N=40 Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment — 2.46; 3.61 percentage of liver fat content
Phase 1 N=44 A Study of Vonoprazan in Adults With Helicobacter Pylori
Helicobacter Pylori
Primary: Cmax: Maximum Observed Plasma Concentration for Bismuth — 42.8; 32.9 nanogram per milliliter (ng/mL)
Phase 4 N=330 Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
Helicobacter Pylori Infection
Primary: Percentage of Helicobacter Pylori Infection Cure — 102; 101; 91 Participants
N/A N=219 The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
Helicobacter Infection
Primary: Number of Participants in Each Arm/Group With Successful H. Pylori Eradication — 67; 63; 36 participants
Phase 4 N=924 Clarithromycin Resistant Tailored Therapy
Peptic Ulcer · Helicobacter Pylori Infection
Primary: Helicobacter Pylori Eradication Rate — 75.9; 91.2; 79.1 percentage of participants
Phase 3 N=40 Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Primary: Percentage of Participants With H.Pylori Infection Eradication — 61 percentage of participants
Phase 4 N=123 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Helicobacter Pylori Infection
Primary: Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped. — 1; 3; 1; 0 participants
N/A N=157 i-Scan for the Detection of Helicobacter Pylori
Gastritis
Primary: Successful Diagnosis of Helicobacter Pylori Using Imaging Modality — 28; 125 Participants
N/A N=330 Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 154; 154 participants
Phase 3 N=282 Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
Helicobacter Pylori Infection
Primary: Sensitivity is Described as the Accuracy of the Breath Test in Detecting H.Pylori Infection Compared to Biopsy — 98.32; 98.53 Percent positive agreement
Phase 3 N=440 Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
Helicobacter Infections
Primary: Helicobacter Pylori Eradication Confirmed by Urea Breath Test — 166; 112 Participants
N/A N=99,314 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
Colorectal Cancer · Stomach Disease
Primary: Incidence of Stomach Cancer — 49; 59 Participants
N/A N=440 Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 206; 191 participants — p=<0.05
Phase 4 N=112 High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
Helicobacter Pylori Infection
Primary: Number of Participant With Eradication of Disease — 37; 42 Participants
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
N/A N=60 Proton Pump Inhibitors and Dysbiosis in Cirrhosis
Cirrhosis · Healthy
Primary: Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation — 45; 15 Participants
Phase 1 N=63 Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults
Helicobacter Pylori Infection
Primary: The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo. — 0; 0; 21; 8 Percentage of subjects